Keros Therapeutics, Inc. Stock Price, News & Analysis

Keros Therapeutics (NASDAQ: KROS), a clinical-stage biopharmaceutical company specializing in TGF-ß family protein signaling disorders, has announced its upcoming participation in the Guggenheim SMID Cap Biotech Conference. The company's Chair and CEO, Jasbir S. Seehra, Ph.D., will engage in a fireside chat presentation on Thursday, February 6, 2025, at 10:00 a.m. Eastern time.

The presentation will be accessible through a live audio webcast at the provided link, and an archived version will remain available on the Keros website's Investor section for up to 90 days after the event. This presentation represents an opportunity for investors and interested parties to gain insights into the company's developments and strategies.

Keros Therapeutics (Nasdaq: KROS) announced the effectiveness of its global development and commercialization license agreement with Takeda (TSE:4502/NYSE:TAK) for elritercept, effective January 16, 2025. The agreement, initially announced on December 3, 2024, was finalized following the expiration of the Hart-Scott Rodino Antitrust Improvements Act waiting period. As part of the agreement, Takeda will make an upfront payment of $200.0 million to Keros, a clinical-stage biopharmaceutical company focused on developing therapeutics for disorders linked to dysfunctional TGF-ß family protein signaling.

Keros Therapeutics (NASDAQ: KROS) has announced the complete halt of dosing in its Phase 2 TROPOS trial of cibotercept (KER-012) for pulmonary arterial hypertension (PAH) due to new observations of pericardial effusion adverse events. This decision extends to all treatment arms, including the 1.5 mg/kg and placebo groups, following a previous halt of the 3.0 mg/kg and 4.5 mg/kg treatment arms announced on December 12, 2024.

The company has notified investigators and regulatory authorities, including the FDA, about the early termination of the trial. Patients will be monitored through end-of-trial visits. Despite the setback, Keros maintains its timeline to present topline data from all treatment arms in the second quarter of 2025.

Keros Therapeutics (NASDAQ: KROS) has announced the voluntary halt of dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms of its Phase 2 TROPOS trial, which studies cibotercept (KER-012) for pulmonary arterial hypertension (PAH). This decision follows the unanticipated observation of pericardial effusion adverse events.

The 1.5 mg/kg treatment arm continues following a risk-benefit assessment by the independent Data Monitoring Committee and Keros team. The trial is fully enrolled, and the company maintains its timeline to present topline data from all treatment arms in Q2 2025. The FDA and other regulatory authorities have been notified of these developments.

Keros Therapeutics (KROS) presented data from two ongoing Phase 2 clinical trials of elritercept at the 66th ASH Annual Meeting. The first trial in lower-risk myelodysplastic syndromes (MDS) showed that 55.2% of patients achieved overall erythroid response, with a median transfusion independence duration of 134.1 weeks. Of high transfusion burden patients, 31.4% achieved transfusion independence for at least eight weeks.

The second trial in myelofibrosis (MF) demonstrated that 82.8% of non-transfusion dependent patients showed increased hemoglobin levels, while 63.4% of transfusion-dependent patients showed reduced transfusion burden. Additionally, 40% of patients showed reduced spleen volume, and 66.7% experienced reduced disease symptoms at week 24.

Elritercept was generally well-tolerated in both trials, with most adverse events being mild to moderate.

Keros Therapeutics (NASDAQ: KROS) has entered into an exclusive global license agreement with Takeda for elritercept, a drug currently in Phase 2 clinical trials for myelodysplastic syndrome (MDS) and myelofibrosis (MF). Under the agreement, Takeda will obtain exclusive rights to develop, manufacture, and commercialize elritercept worldwide, except for mainland China, Hong Kong, and Macau. Keros will receive a $200 million upfront payment and is eligible for additional milestone payments potentially exceeding $1.1 billion, plus tiered royalties on net sales. The deal is expected to extend Keros' operational runway into Q4 2028.

Takeda has entered into an exclusive licensing agreement with Keros Therapeutics for elritercept, a late-stage activin inhibitor designed to treat anemia in hematologic cancers. The agreement grants Takeda exclusive global rights outside mainland China, Hong Kong, and Macau. Elritercept targets myelodysplastic syndromes (MDS) and myelofibrosis (MF), and has received FDA Fast Track designation for MDS treatment. The drug has shown promising clinical activity in early studies. Takeda will pay $200 million upfront, plus potential milestone payments and royalties. Two Phase 2 trials are ongoing, with a Phase 3 RENEW trial for MDS patients starting soon.

Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company specializing in TGF-ß family protein signaling disorders, has announced its participation in two upcoming healthcare conferences. The company's CEO, Jasbir S. Seehra, Ph.D., will present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 10:30 a.m. ET, and the 7th Annual Evercore HealthCONx Conference on December 4, 2024, at 3:00 p.m. ET. Both presentations will be in a fireside chat format, with archived replays available on the Keros website for 90 days after each event.

Keros Therapeutics (NASDAQ: KROS) reported its Q3 2024 financial results and business highlights. The company announced completion of enrollment ahead of schedule in Phase 2 TROPOS trial of cibotercept. Financial results showed a net loss of $53.0 million compared to $39.4 million in Q3 2023. R&D expenses increased to $49.2 million from $34.1 million year-over-year. The company's cash position strengthened to $530.7 million, expected to fund operations into Q3 2027. Keros also appointed Yung H. Chyung as Chief Medical Officer effective November 1, 2024.